Geode Capital Management’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $29.4M | Buy |
1,158,693
+14,873
| +1% | +$352K | ﹤0.01% | 1938 |
|
|
2026
Q1 | $25.9M | Sell |
1,143,820
-25,771
| -2% | -$573K | ﹤0.01% | 1856 |
|
|
2025
Q4 | $30.3M | Sell |
1,169,591
-46,284
| -4% | -$1.1M | ﹤0.01% | 1781 |
|
|
2025
Q3 | $31.3M | Buy |
1,215,875
+72,685
| +6% | +$1.79M | ﹤0.01% | 1768 |
|
|
2025
Q2 | $27.3M | Buy |
1,143,190
+5,658
| +0.5% | +$143K | ﹤0.01% | 1797 |
|
|
2025
Q1 | $28.3M | Buy |
1,137,532
+45,562
| +4% | +$1.09M | ﹤0.01% | 1707 |
|
|
2024
Q4 | $20.6M | Buy |
1,091,970
+5,071
| +0.5% | +$89K | ﹤0.01% | 1958 |
|
|
2024
Q3 | $16.4M | Sell |
1,086,899
-2,405
| -0.2% | -$41.1K | ﹤0.01% | 2091 |
|
|
2024
Q2 | $31.2M | Buy |
1,089,304
+52,623
| +5% | +$1.5M | ﹤0.01% | 1677 |
|
|
2024
Q1 | $30.3M | Buy |
1,036,681
+33,064
| +3% | +$1.02M | ﹤0.01% | 1680 |
|
|
2023
Q4 | $33.9M | Buy |
1,003,617
+47,240
| +5% | +$1.38M | ﹤0.01% | 1594 |
|
|
2023
Q3 | $29.3M | Buy |
956,377
+36,776
| +4% | +$1.33M | ﹤0.01% | 1570 |
|
|
2023
Q2 | $36.8M | Buy |
919,601
+36,817
| +4% | +$1.52M | ﹤0.01% | 1446 |
|
|
2023
Q1 | $36M | Buy |
882,784
+36,621
| +4% | +$1.46M | ﹤0.01% | 1411 |
|
|
2022
Q4 | $32.7M | Buy |
846,163
+26,833
| +3% | +$1.31M | ﹤0.01% | 1442 |
|
|
2022
Q3 | $43.6M | Buy |
819,330
+22,177
| +3% | +$1.23M | 0.01% | 1171 |
|
|
2022
Q2 | $46.5M | Buy |
797,153
+6,341
| +0.8% | +$415K | 0.01% | 1184 |
|
|
2022
Q1 | $60.4M | Sell |
790,812
-46,321
| -6% | -$3.09M | 0.01% | 1119 |
|
|
2021
Q4 | $50.4M | Buy |
837,133
+8,484
| +1% | +$468K | 0.01% | 1309 |
|
|
2021
Q3 | $46.4M | Buy |
828,649
+1,222
| +0.1% | +$70.4K | 0.01% | 1341 |
|
|
2021
Q2 | $50.2M | Buy |
827,427
+34,365
| +4% | +$2.18M | 0.01% | 1305 |
|
|
2021
Q1 | $55.6M | Buy |
793,062
+50,220
| +7% | +$3.59M | 0.01% | 1139 |
|
|
2020
Q4 | $44.5M | Buy |
742,842
+52,106
| +8% | +$3.05M | 0.01% | 1181 |
|
|
2020
Q3 | $41.5M | Sell |
690,736
-13,826
| -2% | -$803K | 0.01% | 1014 |
|
|
2020
Q2 | $37M | Buy |
704,562
+32,479
| +5% | +$1.36M | 0.01% | 1069 |
|
|
2020
Q1 | $22.5M | Buy |
672,083
+32,264
| +5% | +$1.34M | 0.01% | 1216 |
|
|
2019
Q4 | $29M | Buy |
639,819
+20,203
| +3% | +$858K | 0.01% | 1314 |
|
|
2019
Q3 | $23.6M | Buy |
619,616
+6,796
| +1% | +$271K | 0.01% | 1372 |
|
|
2019
Q2 | $26.7M | Buy |
612,820
+63,996
| +12% | +$2.72M | 0.01% | 1287 |
|
|
2019
Q1 | $20.9M | Buy |
548,824
+32,050
| +6% | +$1.25M | 0.01% | 1390 |
|
|
2018
Q4 | $22.2M | Buy |
516,774
+35,635
| +7% | +$1.66M | 0.01% | 1210 |
|
|
2018
Q3 | $23.6M | Buy |
481,139
+26,407
| +6% | +$1.14M | 0.01% | 1289 |
|
|
2018
Q2 | $14.6M | Buy |
454,732
+37,333
| +9% | +$1.29M | ﹤0.01% | 1585 |
|
|
2018
Q1 | $13M | Sell |
417,399
-3,838
| -0.9% | -$137K | ﹤0.01% | 1575 |
|
|
2017
Q4 | $19.2M | Buy |
421,237
+4,562
| +1% | +$181K | 0.01% | 1294 |
|
|
2017
Q3 | $15.6M | Buy |
416,675
+14,025
| +3% | +$564K | 0.01% | 1425 |
|
|
2017
Q2 | $19.2M | Buy |
402,650
+35,561
| +10% | +$1.65M | 0.01% | 1216 |
|
|
2017
Q1 | $16.7M | Buy |
367,089
+18,559
| +5% | +$802K | 0.01% | 1282 |
|
|
2016
Q4 | $11.3M | Buy |
348,530
+48,078
| +16% | +$1.6M | 0.01% | 1491 |
|
|
2016
Q3 | $10.3M | Buy |
300,452
+6,587
| +2% | +$258K | 0.01% | 1480 |
|
|
2016
Q2 | $9.91M | Buy |
293,865
+31,329
| +12% | +$1.54M | 0.01% | 1431 |
|
|
2016
Q1 | $13.9K | Buy |
262,536
+13,435
| +5% | +$786K | 0.01% | 1145 |
|
|
2015
Q4 | $19.1M | Buy |
249,101
+8,724
| +4% | +$494K | 0.01% | 921 |
|
|
2015
Q3 | $9.88M | Buy |
240,377
+4,114
| +2% | +$252K | 0.01% | 1347 |
|
|
2015
Q2 | $16.7M | Buy |
236,263
+8,064
| +4% | +$635K | 0.01% | 1046 |
|
|
2015
Q1 | $20.3M | Buy |
228,199
+12,796
| +6% | +$1.3M | 0.01% | 916 |
|
|
2014
Q4 | $19.1M | Buy |
215,403
+3,040
| +1% | +$288K | 0.01% | 894 |
|
|
2014
Q3 | $20.6M | Buy |
212,363
+2,564
| +1% | +$249K | 0.01% | 807 |
|
|
2014
Q2 | $19.3M | Buy |
209,799
+23,125
| +12% | +$1.76M | 0.01% | 872 |
|
|
2014
Q1 | $13.1M | Buy |
186,674
+16,195
| +9% | +$1.1M | 0.01% | 1061 |
|
|
2013
Q4 | $9.8M | Buy |
170,479
+10,686
| +7% | +$562K | 0.01% | 1198 |
|
|
2013
Q3 | $7.68M | Buy |
159,793
+46,460
| +41% | +$1.69M | 0.01% | 1253 |
|
|
2013
Q2 | $3.29M | Buy |
+113,333
| New | +$3.28M | ﹤0.01% | 1726 |
|
Other funds holding PCRX
DPCM
Geode Capital Management's PCRX Position: Q2 2026 in Review
Geode Capital Management increased its Pacira BioSciences (PCRX) stake by 1.3% in Q2 2026, buying an estimated $352K and bringing the position to 1,158,693 shares worth $29.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1938.
Geode Capital Management first reported a position in PCRX in Q2 2013 and has held it in 53 quarters since. The position peaked at $60.4M in Q1 2022. 233 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.
- Geode Capital Management held 1,158,693 shares of Pacira BioSciences worth $29.4M as of Q2 2026.
- Geode Capital Management bought 14,873 Pacira BioSciences shares in Q2 2026, an estimated $352K.
- Pacira BioSciences made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1938 holding.
- Geode Capital Management first reported a position in Pacira BioSciences in Q2 2013 and has held it in 53 quarters since.
- Geode Capital Management's Pacira BioSciences position peaked at $60.4M in Q1 2022.
- 233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.